Jump to content

Tyrosine-protein kinase SYK: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
KolbertBot (talk | contribs)
Bots
1,166,042 edits
OAbot (talk | contribs)
Bots
438,441 edits
m Open access bot: doi updated in citation with #oabot.
 
(43 intermediate revisions by 30 users not shown)
Line 1: Line 1:
{{cs1 config|name-list-style=vanc}}
{{For|the school abbreviated SYK|Helsingin Suomalainen Yhteiskoulu}}
{{Infobox_gene}}
{{Infobox_gene}}
'''Spleen tyrosine kinase''', also known as '''Syk''', is an [[enzyme]] which in humans is encoded by the ''SYK'' ''gene''.<ref name="entrez">{{cite web | title = Entrez Gene: SYK Spleen tyrosine kinase | url = https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=6850| accessdate = }}</ref><ref name="pmid1423621">{{cite journal | vauthors = Chan AC, Iwashima M, Turck CW, Weiss A | title = ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain | journal = Cell | volume = 71 | issue = 4 | pages = 649–62 | date = November 1992 | pmid = 1423621 | doi = 10.1016/0092-8674(92)90598-7 }}</ref><ref name="pmid8082894">{{cite journal | vauthors = Ku G, Malissen B, Mattei MG | title = Chromosomal location of the Syk and ZAP-70 tyrosine kinase genes in mice and humans | journal = Immunogenetics | volume = 40 | issue = 4 | pages = 300–2 | year = 1994 | pmid = 8082894 | doi = 10.1007/BF00189976 }}</ref>
'''Tyrosine-protein kinase SYK''', also known as '''spleen tyrosine kinase''', is an [[enzyme]] which in humans is encoded by the ''SYK'' [[gene]].<ref name="entrez">{{cite web | title = Entrez Gene: SYK Spleen tyrosine kinase | url = https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=6850}}</ref><ref name="pmid1423621">{{cite journal | vauthors = Chan AC, Iwashima M, Turck CW, Weiss A | title = ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain | journal = Cell | volume = 71 | issue = 4 | pages = 649–62 | date = November 1992 | pmid = 1423621 | doi = 10.1016/0092-8674(92)90598-7 | s2cid = 54326428 }}</ref><ref name="pmid8082894">{{cite journal | vauthors = Ku G, Malissen B, Mattei MG | title = Chromosomal location of the Syk and ZAP-70 tyrosine kinase genes in mice and humans | journal = Immunogenetics | volume = 40 | issue = 4 | pages = 300–2 | year = 1994 | pmid = 8082894 | doi = 10.1007/BF00189976 | s2cid = 33774157 }}</ref>


== Function ==
== Function ==


SYK, along with [[Zap-70]], is a member of the Syk family of [[tyrosine kinase]]s. These non-receptor cytoplasmic tyrosine kinases share a characteristic dual [[SH2 domain]] separated by a linker domain.<ref name="Seda_2015">{{cite journal | vauthors = Seda V, Mraz M | title = B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells | journal = European Journal of Haematology | volume = 94 | issue = 3 | pages = 193–205 | date = March 2015 | pmid = 25080849 | doi = 10.1111/ejh.12427 }}</ref> However, activation of SYK relies less on phosporylation by Src family kinases than Zap-70.<ref>{{cite journal | vauthors = Fasbender F, Claus M, Wingert S, Sandusky M, Watzl C | title = Differential Requirements for Src-Family Kinases in SYK or ZAP70-Mediated SLP-76 Phosphorylation in Lymphocytes | journal = Frontiers in Immunology | volume = 8 | pages = 789 | date = 2017-07-07 | pmid = 28736554 | pmc = 5500614 | doi = 10.3389/fimmu.2017.00789 }}</ref>
SYK, along with [[ZAP70]], is a member of the Syk family of [[tyrosine kinase]]s. These cytoplasmic [[non-receptor tyrosine kinase]]s share a characteristic dual [[SH2 domain]] separated by a linker domain. However, activation of SYK relies less on phosphorylation by Src family kinases than ZAP70.<ref>{{cite journal | vauthors = Fasbender F, Claus M, Wingert S, Sandusky M, Watzl C | title = Differential Requirements for Src-Family Kinases in SYK or ZAP70-Mediated SLP-76 Phosphorylation in Lymphocytes | journal = Frontiers in Immunology | volume = 8 | pages = 789 | date = 2017-07-07 | pmid = 28736554 | pmc = 5500614 | doi = 10.3389/fimmu.2017.00789 | doi-access = free }}</ref> SYK and ZAP70 share a common [[evolution|evolutionary]] origin and split from a [[Most recent common ancestor|common ancestor]] in the [[jawed vertebrates]].<ref name="pmid29881386">{{cite journal | vauthors = Staal J, Driege Y, Haegman M, Borghi A, Hulpiau P, Lievens L, Gul IS, Sundararaman S, Gonçalves A, Dhondt I, Pinzón JH, Braeckman BP, Technau U, Saeys Y, van Roy F, Beyaert R | display-authors = 6 | title = Ancient Origin of the CARD-Coiled Coil/Bcl10/MALT1-Like Paracaspase Signaling Complex Indicates Unknown Critical Functions | journal = Frontiers in Immunology | volume = 9 | issue = | pages = 1136 | year = 2018 | pmid = 29881386 | pmc = 5978004 | doi = 10.3389/fimmu.2018.01136 | doi-access = free }}</ref>


While Syk and Zap-70 are primarily expressed in hematopoietic tissues, there is expression of Syk in a variety of tissues. Within [[B cell|B]] and [[T cell]]s respectively, Syk and Zap-70 transmit signals from the B-Cell receptor and T-Cell receptor.<ref name="Seda_2015"/> Syk plays a similar role in transmitting signals from a variety of cell surface receptors including CD74, [[Fc Receptor]], and [[integrin]]s.
While Syk and ZAP70 are primarily expressed in hematopoietic tissues, a variety of tissues express Syk. Within [[B cell|B]] and [[T cell]]s, respectively, Syk and ZAP70 transmit signals from the [[B-cell receptor]] and [[T-cell receptor]].<ref>{{cite journal | vauthors = Mócsai A, Ruland J, Tybulewicz VL | title = The SYK tyrosine kinase: a crucial player in diverse biological functions | journal = Nature Reviews. Immunology | volume = 10 | issue = 6 | pages = 387–402 | date = June 2010 | pmid = 20467426 | doi = 10.1038/nri2765 | pmc = 4782221 }}</ref> Syk plays a similar role in transmitting signals from a variety of cell surface receptors including [[CD74]], [[Fc receptor]], and [[integrin]]s.


=== Function during development ===
=== Function during development ===
Mice that lack Syk completely (Syk<sup>−/−</sup>, Syk-knockout) die during embryonic development around midgestation. They show severe defects in the development of the lymphatic system. Normally, the lymphatic system and the blood system are strictly separated from each other. However, in Syk deficient mice the lymphatics and the blood vessels form abnormal shunts, leading to leakage of blood into the lymphatic system. The reason for this phenotype was identified by a genetic fate mapping approach, showing that Syk is expressed in myeloid cells which orchestrate the proper separation of lymphatics and blood system during embryogenesis and beyond. Thus, Syk is an essential regulator of the lymphatic system development in mice.<ref name="pmid20230750">{{cite journal | vauthors = Böhmer R, Neuhaus B, Bühren S, Zhang D, Stehling M, Böck B, Kiefer F | title = Regulation of developmental lymphangiogenesis by Syk(+) leukocytes | journal = Developmental Cell | volume = 18 | issue = 3 | pages = 437–49 | date = March 2010 | pmid = 20230750 | doi = 10.1016/j.devcel.2010.01.009 }}</ref>
Mice that lack Syk completely (Syk<sup>−/−</sup>, Syk-knockout) die during embryonic development around midgestation. They show severe defects in the development of the lymphatic system. Normally, the lymphatic system and the blood system are strictly separated from each other. However, in Syk deficient mice the lymphatics and the blood vessels form abnormal shunts, leading to leakage of blood into the lymphatic system. The reason for this phenotype was identified by a genetic fate mapping approach, showing that Syk is expressed in myeloid cells which orchestrate the proper separation of lymphatics and blood system during embryogenesis and beyond. Thus, Syk is an essential regulator of the lymphatic system development in mice.<ref name="pmid20230750">{{cite journal | vauthors = Böhmer R, Neuhaus B, Bühren S, Zhang D, Stehling M, Böck B, Kiefer F | title = Regulation of developmental lymphangiogenesis by Syk(+) leukocytes | journal = Developmental Cell | volume = 18 | issue = 3 | pages = 437–49 | date = March 2010 | pmid = 20230750 | doi = 10.1016/j.devcel.2010.01.009 | doi-access = free }}</ref>


== Clinical significance ==
== Clinical significance ==


Abnormal function of Syk has been implicated in several instances of hematopoeitic malignancies including translocations involving [[ITK (gene)|Itk]] and [[ETV6|Tel]]. Constitutive Syk activity can transform B cells.<ref name="Seda_2015"/> Several transforming viruses contain "[[Immunoreceptor tyrosine-based activation motif|Immunoreceptor Tyrosine Activation Motifs]]" (ITAMs) which lead to activation of Syk including [[Epstein-Barr virus|Epstein Barr virus]], [[bovine leukemia virus]], and [[mouse mammary tumor virus]].
Abnormal function of Syk has been implicated in several instances of hematopoietic malignancies including translocations involving [[ITK (gene)|Itk]] and [[ETV6|Tel]]. Constitutive Syk activity can transform B cells. Several transforming viruses contain "[[Immunoreceptor tyrosine-based activation motif|Immunoreceptor Tyrosine Activation Motifs]]" (ITAMs) which lead to activation of Syk including [[Epstein–Barr virus]], [[bovine leukemia virus]], and [[mouse mammary tumor virus]].


===SYK inhibition===
===SYK inhibition===
Given the central role of SYK in transmission of activating signals within B-cells, a suppression of this tyrosine kinase might aid in the treatment of B cell malignancies and [[autoimmune disease]]s.<ref name="Seda_2015" />
Given the central role of SYK in transmission of activating signals within B-cells, a suppression of this tyrosine kinase might aid in the treatment of B cell malignancies and [[autoimmune disease]]s.{{citation needed|date=November 2018}}


Syk inhibition has been proposed as a therapy for both [[lymphoma]] and [[chronic lymphocytic leukemia]].<ref name="Seda_2015"/> Syk inhibitors are in clinical development, including GS-9973 <ref name="Seda_2015"/> now named [[entospletinib]].<ref name="pmid27247756">{{cite journal | vauthors = Sharman J, Di Paolo J | title = Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib | journal = Therapeutic Advances in Hematology | volume = 7 | issue = 3 | pages = 157–70 | year = 2016 | pmid = 27247756 | pmc = 4872176 | doi = 10.1177/2040620716636542 }}</ref> Other inhibitors of [[B-cell receptor]] (BCR) signaling including [[ibrutinib]] (PCI-32765) which inhibits BTK,<ref name="pmid27641927">{{cite journal | vauthors = Roskoski R | title = Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms | journal = Pharmacological Research | volume = 113 | issue = Pt A | pages = 395–408 | year = 2016 | pmid = 27641927 | doi = 10.1016/j.phrs.2016.09.011 }}</ref> and [[idelalisib]] (PI3K inhibitor - CAL-101 / GS-1101) showed activity in the diseases as well.<ref name="pmid27252232">{{cite journal | vauthors = Cheah CY, Fowler NH | title = Idelalisib in the management of lymphoma | journal = Blood | volume = 128 | issue = 3 | pages = 331–6 | year = 2016 | pmid = 27252232 | doi = 10.1182/blood-2016-02-702761 }}</ref>
Syk inhibition has been proposed as a therapy for both [[lymphoma]] and [[chronic lymphocytic leukemia]].{{citation needed|date=November 2018}} Syk inhibitors are in clinical development, including [[cerdulatinib]] and [[entospletinib]].<ref name="pmid27247756">{{cite journal | vauthors = Sharman J, Di Paolo J | title = Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib | journal = Therapeutic Advances in Hematology | volume = 7 | issue = 3 | pages = 157–70 | year = 2016 | pmid = 27247756 | pmc = 4872176 | doi = 10.1177/2040620716636542 }}</ref> Other inhibitors of [[B-cell receptor]] (BCR) signaling including [[ibrutinib]] (PCI-32765) which inhibits BTK,<ref name="pmid27641927">{{cite journal | vauthors = Roskoski R | title = Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms | journal = Pharmacological Research | volume = 113 | issue = Pt A | pages = 395–408 | year = 2016 | pmid = 27641927 | doi = 10.1016/j.phrs.2016.09.011 }}</ref> and [[idelalisib]] (PI3K inhibitor - CAL-101 / GS-1101) showed activity in the diseases as well.<ref name="pmid27252232">{{cite journal | vauthors = Cheah CY, Fowler NH | title = Idelalisib in the management of lymphoma | journal = Blood | volume = 128 | issue = 3 | pages = 331–6 | year = 2016 | pmid = 27252232 | doi = 10.1182/blood-2016-02-702761 | pmc=5161010}}</ref>


The orally active SYK inhibitor [[fostamatinib]] (R788) in the treatment of [[rheumatoid arthritis]].<ref name="pmid24610702">{{cite journal | vauthors = Scott IC, Scott DL | title = Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now? | journal = Drugs | volume = 74 | issue = 4 | pages = 415–22 | year = 2014 | pmid = 24610702 | doi = 10.1007/s40265-014-0193-9 }}</ref>
The orally active SYK inhibitor [[fostamatinib]] (R788) in the treatment of [[immune thrombocytopenia]].<ref name="pmid24610702">{{cite journal | vauthors = Scott IC, Scott DL | title = Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now? | journal = Drugs | volume = 74 | issue = 4 | pages = 415–22 | year = 2014 | pmid = 24610702 | doi = 10.1007/s40265-014-0193-9 | s2cid = 24168330 }}</ref>


The Syk inhibitor [[nilvadipine]] has been shown to regulate amyloid-β production and [[Tau protein|Tau]] phosphorylation and hence has been proposed as a treatment for [[Alzheimer's Disease]]<ref>{{cite journal | vauthors = Paris D, Ait-Ghezala G, Bachmeier C, Laco G, Beaulieu-Abdelahad D, Lin Y, Jin C, Crawford F, Mullan M | title = The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation | journal = The Journal of Biological Chemistry | volume = 289 | issue = 49 | pages = 33927-44 | date = December 2014 | pmid = 25331948 | pmc = 4256331 | doi = 10.1074/jbc.M114.608091 }}</ref> and has entered phase III clinical trials.<ref>{{cite web | url = https://clinicaltrials.gov/ct2/show/NCT02017340 | title = A Phase III Trial of Nilvadipine to Treat Alzheimer's Disease | work = ClinicalTrials.gov | access-date=2017-04-02}}</ref>
The Syk inhibitor [[nilvadipine]] has been shown to regulate amyloid-β production and [[Tau protein|Tau]] phosphorylation and hence has been proposed as a treatment for [[Alzheimer's disease]]<ref>{{cite journal | vauthors = Paris D, Ait-Ghezala G, Bachmeier C, Laco G, Beaulieu-Abdelahad D, Lin Y, Jin C, Crawford F, Mullan M | title = The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation | journal = The Journal of Biological Chemistry | volume = 289 | issue = 49 | pages = 33927–44 | date = December 2014 | pmid = 25331948 | pmc = 4256331 | doi = 10.1074/jbc.M114.608091 | doi-access = free }}</ref> and has entered phase III clinical trials.<ref>{{cite journal | url = https://clinicaltrials.gov/ct2/show/NCT02017340 | title = A Phase III Trial of Nilvadipine to Treat Alzheimer's Disease | journal = ClinicalTrials.gov | date = 3 March 2017 | access-date=2017-04-02| last1 = Lawlor | first1 = Prof Brian }}</ref>


===Epithelial malignancies===
===Epithelial malignancies===
The role of Syk in epithelial malignancies is controversial. Several authors have suggested that abnormal Syk function facilitates transformation in [[Nasopharyngeal carcinoma]] and [[head and neck cancer]] while other authors have suggested a tumor suppressor role in [[breast cancer|breast]] and [[gastric cancer]].
The role of Syk in epithelial malignancies is controversial. Several authors have suggested that abnormal Syk function facilitates transformation in [[Nasopharyngeal carcinoma]] and [[head and neck cancer]] while other authors have suggested a tumor suppressor role in [[breast cancer|breast]] and [[gastric cancer]].


Without Syk, the protein it makes, and genetic disruption in a panel of 55 genes thought also to be controlled by Syk, [[breast ductal carcinoma in situ]] (breast DCIS, which can become invasive), it is believed that the cancer has a markedly increased tendency to invade and metastasize.<ref name="pmid24523870">{{cite journal | vauthors = Blancato J, Graves A, Rashidi B, Moroni M, Tchobe L, Ozdemirli M, Kallakury B, Makambi KH, Marian C, Mueller SC | title = SYK allelic loss and the role of Syk-regulated genes in breast cancer survival | journal = Plos One | volume = 9 | issue = 2 | pages = e87610 | year = 2014 | pmid = 24523870 | pmc = 3921124 | doi = 10.1371/journal.pone.0087610 }}</ref>
Without Syk, the protein it makes, and genetic disruption in a panel of 55 genes thought also to be controlled by Syk, [[breast]] [[ductal carcinoma in situ]] (breast DCIS, which can become invasive), it is believed that the cancer has a markedly increased tendency to invade and metastasize.<ref name="pmid24523870">{{cite journal | vauthors = Blancato J, Graves A, Rashidi B, Moroni M, Tchobe L, Ozdemirli M, Kallakury B, Makambi KH, Marian C, Mueller SC | title = SYK allelic loss and the role of Syk-regulated genes in breast cancer survival | journal = PLOS ONE | volume = 9 | issue = 2 | pages = e87610 | year = 2014 | pmid = 24523870 | pmc = 3921124 | doi = 10.1371/journal.pone.0087610 | bibcode = 2014PLoSO...987610B | doi-access = free }}</ref>


== Interactions ==
== Interactions ==
Line 34: Line 34:
Syk has been shown to [[Protein-protein interaction|interact]] with:
Syk has been shown to [[Protein-protein interaction|interact]] with:


* [[Cbl gene]]<ref name=pmid11331248/><ref name="pmid9857068">{{cite journal | vauthors = Lupher ML, Rao N, Lill NL, Andoniou CE, Miyake S, Clark EA, Druker B, Band H | title = Cbl-mediated negative regulation of the Syk tyrosine kinase. A critical role for Cbl phosphotyrosine-binding domain binding to Syk phosphotyrosine 323 | journal = The Journal of Biological Chemistry | volume = 273 | issue = 52 | pages = 35273–81 | date = December 1998 | pmid = 9857068 | doi = 10.1074/jbc.273.52.35273 }}</ref><ref name="pmid12435267">{{cite journal | vauthors = Melander F, Andersson T, Dib K | title = Fgr but not Syk tyrosine kinase is a target for beta 2 integrin-induced c-Cbl-mediated ubiquitination in adherent human neutrophils | journal = The Biochemical Journal | volume = 370 | issue = Pt 2 | pages = 687–94 | date = March 2003 | pmid = 12435267 | pmc = 1223185 | doi = 10.1042/BJ20021201 }}</ref>
* [[Cbl gene]]<ref name=pmid11331248/><ref name="pmid9857068">{{cite journal | vauthors = Lupher ML, Rao N, Lill NL, Andoniou CE, Miyake S, Clark EA, Druker B, Band H | title = Cbl-mediated negative regulation of the Syk tyrosine kinase. A critical role for Cbl phosphotyrosine-binding domain binding to Syk phosphotyrosine 323 | journal = The Journal of Biological Chemistry | volume = 273 | issue = 52 | pages = 35273–81 | date = December 1998 | pmid = 9857068 | doi = 10.1074/jbc.273.52.35273 | doi-access = free }}</ref><ref name="pmid12435267">{{cite journal | vauthors = Melander F, Andersson T, Dib K | title = Fgr but not Syk tyrosine kinase is a target for beta 2 integrin-induced c-Cbl-mediated ubiquitination in adherent human neutrophils | journal = The Biochemical Journal | volume = 370 | issue = Pt 2 | pages = 687–94 | date = March 2003 | pmid = 12435267 | pmc = 1223185 | doi = 10.1042/BJ20021201 }}</ref>
* [[CRKL]],<ref name="pmid11313252">{{cite journal | vauthors = Oda A, Ochs HD, Lasky LA, Spencer S, Ozaki K, Fujihara M, Handa M, Ikebuchi K, Ikeda H | title = CrkL is an adapter for Wiskott-Aldrich syndrome protein and Syk | journal = Blood | volume = 97 | issue = 9 | pages = 2633–9 | date = May 2001 | pmid = 11313252 | doi = 10.1182/blood.V97.9.2633 }}</ref>
* [[CRKL]],<ref name="pmid11313252">{{cite journal | vauthors = Oda A, Ochs HD, Lasky LA, Spencer S, Ozaki K, Fujihara M, Handa M, Ikebuchi K, Ikeda H | title = CrkL is an adapter for Wiskott-Aldrich syndrome protein and Syk | journal = Blood | volume = 97 | issue = 9 | pages = 2633–9 | date = May 2001 | pmid = 11313252 | doi = 10.1182/blood.V97.9.2633 | doi-access = free }}</ref>
* [[FCGR2A]],<ref name="pmid9268059">{{cite journal | vauthors = Ibarrola I, Vossebeld PJ, Homburg CH, Thelen M, Roos D, Verhoeven AJ | title = Influence of tyrosine phosphorylation on protein interaction with FcgammaRIIa | journal = Biochimica et Biophysica Acta | volume = 1357 | issue = 3 | pages = 348–58 | date = July 1997 | pmid = 9268059 | doi = 10.1016/S0167-4889(97)00034-7 }}</ref><ref name="pmid11141335">{{cite journal | vauthors = Kim MK, Pan XQ, Huang ZY, Hunter S, Hwang PH, Indik ZK, Schreiber AD | title = Fc gamma receptors differ in their structural requirements for interaction with the tyrosine kinase Syk in the initial steps of signaling for phagocytosis | journal = Clinical Immunology | volume = 98 | issue = 1 | pages = 125–32 | date = January 2001 | pmid = 11141335 | doi = 10.1006/clim.2000.4955 }}</ref>
* [[FCGR2A]],<ref name="pmid9268059">{{cite journal | vauthors = Ibarrola I, Vossebeld PJ, Homburg CH, Thelen M, Roos D, Verhoeven AJ | title = Influence of tyrosine phosphorylation on protein interaction with FcgammaRIIa | journal = Biochimica et Biophysica Acta (BBA) - Molecular Cell Research | volume = 1357 | issue = 3 | pages = 348–58 | date = July 1997 | pmid = 9268059 | doi = 10.1016/S0167-4889(97)00034-7 | doi-access = free }}</ref><ref name="pmid11141335">{{cite journal | vauthors = Kim MK, Pan XQ, Huang ZY, Hunter S, Hwang PH, Indik ZK, Schreiber AD | title = Fc gamma receptors differ in their structural requirements for interaction with the tyrosine kinase Syk in the initial steps of signaling for phagocytosis | journal = Clinical Immunology | volume = 98 | issue = 1 | pages = 125–32 | date = January 2001 | pmid = 11141335 | doi = 10.1006/clim.2000.4955 }}</ref>
* [[FYN]],<ref name="pmid9535867">{{cite journal | vauthors = Deckert M, Elly C, Altman A, Liu YC | title = Coordinated regulation of the tyrosine phosphorylation of Cbl by Fyn and Syk tyrosine kinases | journal = The Journal of Biological Chemistry | volume = 273 | issue = 15 | pages = 8867–74 | date = April 1998 | pmid = 9535867 | doi = 10.1074/jbc.273.15.8867 }}</ref><ref name="pmid9169439">{{cite journal | vauthors = Chung J, Gao AG, Frazier WA | title = Thrombspondin acts via integrin-associated protein to activate the platelet integrin alphaIIbbeta3 | journal = The Journal of Biological Chemistry | volume = 272 | issue = 23 | pages = 14740–6 | date = June 1997 | pmid = 9169439 | doi = 10.1074/jbc.272.23.14740 }}</ref>
* [[FYN]],<ref name="pmid9535867">{{cite journal | vauthors = Deckert M, Elly C, Altman A, Liu YC | title = Coordinated regulation of the tyrosine phosphorylation of Cbl by Fyn and Syk tyrosine kinases | journal = The Journal of Biological Chemistry | volume = 273 | issue = 15 | pages = 8867–74 | date = April 1998 | pmid = 9535867 | doi = 10.1074/jbc.273.15.8867 | doi-access = free }}</ref><ref name="pmid9169439">{{cite journal | vauthors = Chung J, Gao AG, Frazier WA | title = Thrombspondin acts via integrin-associated protein to activate the platelet integrin alphaIIbbeta3 | journal = The Journal of Biological Chemistry | volume = 272 | issue = 23 | pages = 14740–6 | date = June 1997 | pmid = 9169439 | doi = 10.1074/jbc.272.23.14740 | doi-access = free }}</ref>
* [[Grb2]],<ref name=pmid10747947/><ref name="pmid11964172">{{cite journal | vauthors = Saci A, Liu WQ, Vidal M, Garbay C, Rendu F, Bachelot-Loza C | title = Differential effect of the inhibition of Grb2-SH3 interactions in platelet activation induced by thrombin and by Fc receptor engagement | journal = The Biochemical Journal | volume = 363 | issue = Pt 3 | pages = 717–25 | date = May 2002 | pmid = 11964172 | pmc = 1222524 | doi = 10.1042/0264-6021:3630717 }}</ref>
* [[Grb2]],<ref name=pmid10747947/><ref name="pmid11964172">{{cite journal | vauthors = Saci A, Liu WQ, Vidal M, Garbay C, Rendu F, Bachelot-Loza C | title = Differential effect of the inhibition of Grb2-SH3 interactions in platelet activation induced by thrombin and by Fc receptor engagement | journal = The Biochemical Journal | volume = 363 | issue = Pt 3 | pages = 717–25 | date = May 2002 | pmid = 11964172 | pmc = 1222524 | doi = 10.1042/0264-6021:3630717 }}</ref>
* [[Lck]],<ref name="pmid7539035">{{cite journal | vauthors = Thome M, Duplay P, Guttinger M, Acuto O | title = Syk and ZAP-70 mediate recruitment of p56lck/CD4 to the activated T cell receptor/CD3/zeta complex | journal = The Journal of Experimental Medicine | volume = 181 | issue = 6 | pages = 1997–2006 | date = June 1995 | pmid = 7539035 | pmc = 2192070 | doi = 10.1084/jem.181.6.1997 }}</ref>
* [[Lck]],<ref name="pmid7539035">{{cite journal | vauthors = Thome M, Duplay P, Guttinger M, Acuto O | title = Syk and ZAP-70 mediate recruitment of p56lck/CD4 to the activated T cell receptor/CD3/zeta complex | journal = The Journal of Experimental Medicine | volume = 181 | issue = 6 | pages = 1997–2006 | date = June 1995 | pmid = 7539035 | pmc = 2192070 | doi = 10.1084/jem.181.6.1997 }}</ref>
* [[LYN]],<ref name="pmid7831290">{{cite journal | vauthors = Sidorenko SP, Law CL, Chandran KA, Clark EA | title = Human spleen tyrosine kinase p72Syk associates with the Src-family kinase p53/56Lyn and a 120-kDa phosphoprotein | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 92 | issue = 2 | pages = 359–63 | date = January 1995 | pmid = 7831290 | pmc = 42739 | doi = 10.1073/pnas.92.2.359 }}</ref>
* [[LYN]],<ref name="pmid7831290">{{cite journal | vauthors = Sidorenko SP, Law CL, Chandran KA, Clark EA | title = Human spleen tyrosine kinase p72Syk associates with the Src-family kinase p53/56Lyn and a 120-kDa phosphoprotein | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 92 | issue = 2 | pages = 359–63 | date = January 1995 | pmid = 7831290 | pmc = 42739 | doi = 10.1073/pnas.92.2.359 | bibcode = 1995PNAS...92..359S | doi-access = free }}</ref>
* [[PTK2]],<ref name="pmid9342235">{{cite journal | vauthors = Sada K, Minami Y, Yamamura H | title = Relocation of Syk protein-tyrosine kinase to the actin filament network and subsequent association with Fak | journal = European Journal of Biochemistry | volume = 248 | issue = 3 | pages = 827–33 | date = September 1997 | pmid = 9342235 | doi = 10.1111/j.1432-1033.1997.00827.x }}</ref>
* [[PTK2]],<ref name="pmid9342235">{{cite journal | vauthors = Sada K, Minami Y, Yamamura H | title = Relocation of Syk protein-tyrosine kinase to the actin filament network and subsequent association with Fak | journal = European Journal of Biochemistry | volume = 248 | issue = 3 | pages = 827–33 | date = September 1997 | pmid = 9342235 | doi = 10.1111/j.1432-1033.1997.00827.x | doi-access = free }}</ref>
* [[PTPN6]],<ref name="pmid10747947">{{cite journal | vauthors = Ganju RK, Brubaker SA, Chernock RD, Avraham S, Groopman JE | title = Beta-chemokine receptor CCR5 signals through SHP1, SHP2, and Syk | journal = The Journal of Biological Chemistry | volume = 275 | issue = 23 | pages = 17263–8 | date = June 2000 | pmid = 10747947 | doi = 10.1074/jbc.M000689200 }}</ref><ref name="pmid10072516">{{cite journal | vauthors = Dustin LB, Plas DR, Wong J, Hu YT, Soto C, Chan AC, Thomas ML | title = Expression of dominant-negative src-homology domain 2-containing protein tyrosine phosphatase-1 results in increased Syk tyrosine kinase activity and B cell activation | journal = Journal of Immunology | volume = 162 | issue = 5 | pages = 2717–24 | date = March 1999 | pmid = 10072516 | doi = }}</ref> and
* [[PTPN6]],<ref name="pmid10747947">{{cite journal | vauthors = Ganju RK, Brubaker SA, Chernock RD, Avraham S, Groopman JE | title = Beta-chemokine receptor CCR5 signals through SHP1, SHP2, and Syk | journal = The Journal of Biological Chemistry | volume = 275 | issue = 23 | pages = 17263–8 | date = June 2000 | pmid = 10747947 | doi = 10.1074/jbc.M000689200 | doi-access = free }}</ref><ref name="pmid10072516">{{cite journal | vauthors = Dustin LB, Plas DR, Wong J, Hu YT, Soto C, Chan AC, Thomas ML | title = Expression of dominant-negative src-homology domain 2-containing protein tyrosine phosphatase-1 results in increased Syk tyrosine kinase activity and B cell activation | journal = Journal of Immunology | volume = 162 | issue = 5 | pages = 2717–24 | date = March 1999 | doi = 10.4049/jimmunol.162.5.2717 | pmid = 10072516 | doi-access = free }}</ref> and
* [[VAV1]].<ref name="pmid11331248">{{cite journal | vauthors = Bertagnolo V, Marchisio M, Brugnoli F, Bavelloni A, Boccafogli L, Colamussi ML, Capitani S | title = Requirement of tyrosine-phosphorylated Vav for morphological differentiation of all-trans-retinoic acid-treated HL-60 cells | journal = Cell Growth & Differentiation | volume = 12 | issue = 4 | pages = 193–200 | date = April 2001 | pmid = 11331248 | doi = }}</ref><ref name="pmid8986718">{{cite journal | vauthors = Deckert M, Tartare-Deckert S, Couture C, Mustelin T, Altman A | title = Functional and physical interactions of Syk family kinases with the Vav proto-oncogene product | journal = Immunity | volume = 5 | issue = 6 | pages = 591–604 | date = December 1996 | pmid = 8986718 | doi = 10.1016/S1074-7613(00)80273-3 }}</ref><ref name="pmid8900182">{{cite journal | vauthors = Song JS, Gomez J, Stancato LF, Rivera J | title = Association of a p95 Vav-containing signaling complex with the FcepsilonRI gamma chain in the RBL-2H3 mast cell line. Evidence for a constitutive in vivo association of Vav with Grb2, Raf-1, and ERK2 in an active complex | journal = The Journal of Biological Chemistry | volume = 271 | issue = 43 | pages = 26962–70 | date = October 1996 | pmid = 8900182 | doi = 10.1074/jbc.271.43.26962 }}</ref>
* [[VAV1]].<ref name="pmid11331248">{{cite journal | vauthors = Bertagnolo V, Marchisio M, Brugnoli F, Bavelloni A, Boccafogli L, Colamussi ML, Capitani S | title = Requirement of tyrosine-phosphorylated Vav for morphological differentiation of all-trans-retinoic acid-treated HL-60 cells | journal = Cell Growth & Differentiation | volume = 12 | issue = 4 | pages = 193–200 | date = April 2001 | pmid = 11331248 }}</ref><ref name="pmid8986718">{{cite journal | vauthors = Deckert M, Tartare-Deckert S, Couture C, Mustelin T, Altman A | title = Functional and physical interactions of Syk family kinases with the Vav proto-oncogene product | journal = Immunity | volume = 5 | issue = 6 | pages = 591–604 | date = December 1996 | pmid = 8986718 | doi = 10.1016/S1074-7613(00)80273-3 | doi-access = free }}</ref><ref name="pmid8900182">{{cite journal | vauthors = Song JS, Gomez J, Stancato LF, Rivera J | title = Association of a p95 Vav-containing signaling complex with the FcepsilonRI gamma chain in the RBL-2H3 mast cell line. Evidence for a constitutive in vivo association of Vav with Grb2, Raf-1, and ERK2 in an active complex | journal = The Journal of Biological Chemistry | volume = 271 | issue = 43 | pages = 26962–70 | date = October 1996 | pmid = 8900182 | doi = 10.1074/jbc.271.43.26962 | doi-access = free }}</ref>
{{Clear}}
{{Clear}}


Line 52: Line 52:
{{Refbegin|35em}}
{{Refbegin|35em}}
* {{cite journal | vauthors = Turner M, Schweighoffer E, Colucci F, Di Santo JP, Tybulewicz VL | title = Tyrosine kinase SYK: essential functions for immunoreceptor signalling | journal = Immunology Today | volume = 21 | issue = 3 | pages = 148–54 | date = March 2000 | pmid = 10689303 | doi = 10.1016/S0167-5699(99)01574-1 }}
* {{cite journal | vauthors = Turner M, Schweighoffer E, Colucci F, Di Santo JP, Tybulewicz VL | title = Tyrosine kinase SYK: essential functions for immunoreceptor signalling | journal = Immunology Today | volume = 21 | issue = 3 | pages = 148–54 | date = March 2000 | pmid = 10689303 | doi = 10.1016/S0167-5699(99)01574-1 }}
* {{cite journal | vauthors = Fruman DA, Satterthwaite AB, Witte ON | title = Xid-like phenotypes: a B cell signalosome takes shape | journal = Immunity | volume = 13 | issue = 1 | pages = 1–3 | date = July 2000 | pmid = 10933389 | doi = 10.1016/S1074-7613(00)00002-9 }}
* {{cite journal | vauthors = Fruman DA, Satterthwaite AB, Witte ON | title = Xid-like phenotypes: a B cell signalosome takes shape | journal = Immunity | volume = 13 | issue = 1 | pages = 1–3 | date = July 2000 | pmid = 10933389 | doi = 10.1016/S1074-7613(00)00002-9 | doi-access = free }}
* {{cite journal | vauthors = Yanagi S, Inatome R, Takano T, Yamamura H | title = Syk expression and novel function in a wide variety of tissues | journal = Biochemical and Biophysical Research Communications | volume = 288 | issue = 3 | pages = 495–8 | date = November 2001 | pmid = 11676469 | doi = 10.1006/bbrc.2001.5788 }}
* {{cite journal | vauthors = Yanagi S, Inatome R, Takano T, Yamamura H | title = Syk expression and novel function in a wide variety of tissues | journal = Biochemical and Biophysical Research Communications | volume = 288 | issue = 3 | pages = 495–8 | date = November 2001 | pmid = 11676469 | doi = 10.1006/bbrc.2001.5788 }}
* {{cite journal | vauthors = Tohyama Y, Yamamura H | title = Complement-mediated phagocytosis--the role of Syk | journal = IUBMB Life | volume = 58 | issue = 5-6 | pages = 304–8 | year = 2006 | pmid = 16754322 | doi = 10.1080/15216540600746377 }}
* {{cite journal | vauthors = Tohyama Y, Yamamura H | title = Complement-mediated phagocytosis--the role of Syk | journal = IUBMB Life | volume = 58 | issue = 5–6 | pages = 304–8 | year = 2006 | pmid = 16754322 | doi = 10.1080/15216540600746377 | s2cid = 41684033 | doi-access = free }}
* {{cite journal | vauthors = Schymeinsky J, Mócsai A, Walzog B | title = Neutrophil activation via beta2 integrins (CD11/CD18): molecular mechanisms and clinical implications | journal = Thrombosis and Haemostasis | volume = 98 | issue = 2 | pages = 262–73 | date = August 2007 | pmid = 17721605 | doi = 10.1160/th07-02-0156 }}
* {{cite journal | vauthors = Schymeinsky J, Mócsai A, Walzog B | title = Neutrophil activation via beta2 integrins (CD11/CD18): molecular mechanisms and clinical implications | journal = Thrombosis and Haemostasis | volume = 98 | issue = 2 | pages = 262–73 | date = August 2007 | pmid = 17721605 | doi = 10.1160/th07-02-0156 | s2cid = 41094726 }}
{{Refend}}
{{Refend}}


== External links ==
== External links ==
* {{MeshName|Syk+kinase}}
* {{MeshName|Syk+kinase}}
* {{PDBe-KB2|P43405|Tyrosine-protein kinase SYK}}


{{PDB Gallery|geneid=6850}}
{{PDB Gallery|geneid=6850}}
{{Tyrosine kinases}}
{{Tyrosine kinases}}
{{Enzymes}}
{{Enzymes}}
{{Portal bar|Molecular and Cellular Biology|border=no}}
{{Portal bar|Biology|border=no}}


[[Category:Tyrosine kinases]]
[[Category:Tyrosine kinases]]

Latest revision as of 06:18, 25 December 2023

SYK
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesSYK, p72-Syk, spleen tyrosine kinase, spleen associated tyrosine kinase, IMD82
External IDsOMIM: 600085; MGI: 99515; HomoloGene: 2390; GeneCards: SYK; OMA:SYK - orthologs
Orthologs
SpeciesHumanMouse
Entrez

6850

20963

Ensembl

ENSG00000165025

ENSMUSG00000021457

UniProt

P43405

P48025

RefSeq (mRNA)

NM_001135052
NM_001174167
NM_001174168
NM_003177

NM_001198977
NM_011518

RefSeq (protein)

NP_001128524
NP_001167638
NP_001167639
NP_003168

NP_001185906
NP_035648

Location (UCSC)Chr 9: 90.8 – 90.9 MbChr 13: 52.74 – 52.8 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Tyrosine-protein kinase SYK, also known as spleen tyrosine kinase, is an enzyme which in humans is encoded by the SYK gene.[5][6][7]

Function

[edit]

SYK, along with ZAP70, is a member of the Syk family of tyrosine kinases. These cytoplasmic non-receptor tyrosine kinases share a characteristic dual SH2 domain separated by a linker domain. However, activation of SYK relies less on phosphorylation by Src family kinases than ZAP70.[8] SYK and ZAP70 share a common evolutionary origin and split from a common ancestor in the jawed vertebrates.[9]

While Syk and ZAP70 are primarily expressed in hematopoietic tissues, a variety of tissues express Syk. Within B and T cells, respectively, Syk and ZAP70 transmit signals from the B-cell receptor and T-cell receptor.[10] Syk plays a similar role in transmitting signals from a variety of cell surface receptors including CD74, Fc receptor, and integrins.

Function during development

[edit]

Mice that lack Syk completely (Syk−/−, Syk-knockout) die during embryonic development around midgestation. They show severe defects in the development of the lymphatic system. Normally, the lymphatic system and the blood system are strictly separated from each other. However, in Syk deficient mice the lymphatics and the blood vessels form abnormal shunts, leading to leakage of blood into the lymphatic system. The reason for this phenotype was identified by a genetic fate mapping approach, showing that Syk is expressed in myeloid cells which orchestrate the proper separation of lymphatics and blood system during embryogenesis and beyond. Thus, Syk is an essential regulator of the lymphatic system development in mice.[11]

Clinical significance

[edit]

Abnormal function of Syk has been implicated in several instances of hematopoietic malignancies including translocations involving Itk and Tel. Constitutive Syk activity can transform B cells. Several transforming viruses contain "Immunoreceptor Tyrosine Activation Motifs" (ITAMs) which lead to activation of Syk including Epstein–Barr virus, bovine leukemia virus, and mouse mammary tumor virus.

SYK inhibition

[edit]

Given the central role of SYK in transmission of activating signals within B-cells, a suppression of this tyrosine kinase might aid in the treatment of B cell malignancies and autoimmune diseases.[citation needed]

Syk inhibition has been proposed as a therapy for both lymphoma and chronic lymphocytic leukemia.[citation needed] Syk inhibitors are in clinical development, including cerdulatinib and entospletinib.[12] Other inhibitors of B-cell receptor (BCR) signaling including ibrutinib (PCI-32765) which inhibits BTK,[13] and idelalisib (PI3K inhibitor - CAL-101 / GS-1101) showed activity in the diseases as well.[14]

The orally active SYK inhibitor fostamatinib (R788) in the treatment of immune thrombocytopenia.[15]

The Syk inhibitor nilvadipine has been shown to regulate amyloid-β production and Tau phosphorylation and hence has been proposed as a treatment for Alzheimer's disease[16] and has entered phase III clinical trials.[17]

Epithelial malignancies

[edit]

The role of Syk in epithelial malignancies is controversial. Several authors have suggested that abnormal Syk function facilitates transformation in Nasopharyngeal carcinoma and head and neck cancer while other authors have suggested a tumor suppressor role in breast and gastric cancer.

Without Syk, the protein it makes, and genetic disruption in a panel of 55 genes thought also to be controlled by Syk, breast ductal carcinoma in situ (breast DCIS, which can become invasive), it is believed that the cancer has a markedly increased tendency to invade and metastasize.[18]

Interactions

[edit]

Syk has been shown to interact with:

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000165025 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000021457 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ "Entrez Gene: SYK Spleen tyrosine kinase".
  6. ^ Chan AC, Iwashima M, Turck CW, Weiss A (November 1992). "ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain". Cell. 71 (4): 649–62. doi:10.1016/0092-8674(92)90598-7. PMID 1423621. S2CID 54326428.
  7. ^ Ku G, Malissen B, Mattei MG (1994). "Chromosomal location of the Syk and ZAP-70 tyrosine kinase genes in mice and humans". Immunogenetics. 40 (4): 300–2. doi:10.1007/BF00189976. PMID 8082894. S2CID 33774157.
  8. ^ Fasbender F, Claus M, Wingert S, Sandusky M, Watzl C (2017-07-07). "Differential Requirements for Src-Family Kinases in SYK or ZAP70-Mediated SLP-76 Phosphorylation in Lymphocytes". Frontiers in Immunology. 8: 789. doi:10.3389/fimmu.2017.00789. PMC 5500614. PMID 28736554.
  9. ^ Staal J, Driege Y, Haegman M, Borghi A, Hulpiau P, Lievens L, et al. (2018). "Ancient Origin of the CARD-Coiled Coil/Bcl10/MALT1-Like Paracaspase Signaling Complex Indicates Unknown Critical Functions". Frontiers in Immunology. 9: 1136. doi:10.3389/fimmu.2018.01136. PMC 5978004. PMID 29881386.
  10. ^ Mócsai A, Ruland J, Tybulewicz VL (June 2010). "The SYK tyrosine kinase: a crucial player in diverse biological functions". Nature Reviews. Immunology. 10 (6): 387–402. doi:10.1038/nri2765. PMC 4782221. PMID 20467426.
  11. ^ Böhmer R, Neuhaus B, Bühren S, Zhang D, Stehling M, Böck B, Kiefer F (March 2010). "Regulation of developmental lymphangiogenesis by Syk(+) leukocytes". Developmental Cell. 18 (3): 437–49. doi:10.1016/j.devcel.2010.01.009. PMID 20230750.
  12. ^ Sharman J, Di Paolo J (2016). "Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib". Therapeutic Advances in Hematology. 7 (3): 157–70. doi:10.1177/2040620716636542. PMC 4872176. PMID 27247756.
  13. ^ Roskoski R (2016). "Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms". Pharmacological Research. 113 (Pt A): 395–408. doi:10.1016/j.phrs.2016.09.011. PMID 27641927.
  14. ^ Cheah CY, Fowler NH (2016). "Idelalisib in the management of lymphoma". Blood. 128 (3): 331–6. doi:10.1182/blood-2016-02-702761. PMC 5161010. PMID 27252232.
  15. ^ Scott IC, Scott DL (2014). "Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?". Drugs. 74 (4): 415–22. doi:10.1007/s40265-014-0193-9. PMID 24610702. S2CID 24168330.
  16. ^ Paris D, Ait-Ghezala G, Bachmeier C, Laco G, Beaulieu-Abdelahad D, Lin Y, Jin C, Crawford F, Mullan M (December 2014). "The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation". The Journal of Biological Chemistry. 289 (49): 33927–44. doi:10.1074/jbc.M114.608091. PMC 4256331. PMID 25331948.
  17. ^ Lawlor PB (3 March 2017). "A Phase III Trial of Nilvadipine to Treat Alzheimer's Disease". ClinicalTrials.gov. Retrieved 2017-04-02.
  18. ^ Blancato J, Graves A, Rashidi B, Moroni M, Tchobe L, Ozdemirli M, Kallakury B, Makambi KH, Marian C, Mueller SC (2014). "SYK allelic loss and the role of Syk-regulated genes in breast cancer survival". PLOS ONE. 9 (2): e87610. Bibcode:2014PLoSO...987610B. doi:10.1371/journal.pone.0087610. PMC 3921124. PMID 24523870.
  19. ^ a b Bertagnolo V, Marchisio M, Brugnoli F, Bavelloni A, Boccafogli L, Colamussi ML, Capitani S (April 2001). "Requirement of tyrosine-phosphorylated Vav for morphological differentiation of all-trans-retinoic acid-treated HL-60 cells". Cell Growth & Differentiation. 12 (4): 193–200. PMID 11331248.
  20. ^ Lupher ML, Rao N, Lill NL, Andoniou CE, Miyake S, Clark EA, Druker B, Band H (December 1998). "Cbl-mediated negative regulation of the Syk tyrosine kinase. A critical role for Cbl phosphotyrosine-binding domain binding to Syk phosphotyrosine 323". The Journal of Biological Chemistry. 273 (52): 35273–81. doi:10.1074/jbc.273.52.35273. PMID 9857068.
  21. ^ Melander F, Andersson T, Dib K (March 2003). "Fgr but not Syk tyrosine kinase is a target for beta 2 integrin-induced c-Cbl-mediated ubiquitination in adherent human neutrophils". The Biochemical Journal. 370 (Pt 2): 687–94. doi:10.1042/BJ20021201. PMC 1223185. PMID 12435267.
  22. ^ Oda A, Ochs HD, Lasky LA, Spencer S, Ozaki K, Fujihara M, Handa M, Ikebuchi K, Ikeda H (May 2001). "CrkL is an adapter for Wiskott-Aldrich syndrome protein and Syk". Blood. 97 (9): 2633–9. doi:10.1182/blood.V97.9.2633. PMID 11313252.
  23. ^ Ibarrola I, Vossebeld PJ, Homburg CH, Thelen M, Roos D, Verhoeven AJ (July 1997). "Influence of tyrosine phosphorylation on protein interaction with FcgammaRIIa". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1357 (3): 348–58. doi:10.1016/S0167-4889(97)00034-7. PMID 9268059.
  24. ^ Kim MK, Pan XQ, Huang ZY, Hunter S, Hwang PH, Indik ZK, Schreiber AD (January 2001). "Fc gamma receptors differ in their structural requirements for interaction with the tyrosine kinase Syk in the initial steps of signaling for phagocytosis". Clinical Immunology. 98 (1): 125–32. doi:10.1006/clim.2000.4955. PMID 11141335.
  25. ^ Deckert M, Elly C, Altman A, Liu YC (April 1998). "Coordinated regulation of the tyrosine phosphorylation of Cbl by Fyn and Syk tyrosine kinases". The Journal of Biological Chemistry. 273 (15): 8867–74. doi:10.1074/jbc.273.15.8867. PMID 9535867.
  26. ^ Chung J, Gao AG, Frazier WA (June 1997). "Thrombspondin acts via integrin-associated protein to activate the platelet integrin alphaIIbbeta3". The Journal of Biological Chemistry. 272 (23): 14740–6. doi:10.1074/jbc.272.23.14740. PMID 9169439.
  27. ^ a b Ganju RK, Brubaker SA, Chernock RD, Avraham S, Groopman JE (June 2000). "Beta-chemokine receptor CCR5 signals through SHP1, SHP2, and Syk". The Journal of Biological Chemistry. 275 (23): 17263–8. doi:10.1074/jbc.M000689200. PMID 10747947.
  28. ^ Saci A, Liu WQ, Vidal M, Garbay C, Rendu F, Bachelot-Loza C (May 2002). "Differential effect of the inhibition of Grb2-SH3 interactions in platelet activation induced by thrombin and by Fc receptor engagement". The Biochemical Journal. 363 (Pt 3): 717–25. doi:10.1042/0264-6021:3630717. PMC 1222524. PMID 11964172.
  29. ^ Thome M, Duplay P, Guttinger M, Acuto O (June 1995). "Syk and ZAP-70 mediate recruitment of p56lck/CD4 to the activated T cell receptor/CD3/zeta complex". The Journal of Experimental Medicine. 181 (6): 1997–2006. doi:10.1084/jem.181.6.1997. PMC 2192070. PMID 7539035.
  30. ^ Sidorenko SP, Law CL, Chandran KA, Clark EA (January 1995). "Human spleen tyrosine kinase p72Syk associates with the Src-family kinase p53/56Lyn and a 120-kDa phosphoprotein". Proceedings of the National Academy of Sciences of the United States of America. 92 (2): 359–63. Bibcode:1995PNAS...92..359S. doi:10.1073/pnas.92.2.359. PMC 42739. PMID 7831290.
  31. ^ Sada K, Minami Y, Yamamura H (September 1997). "Relocation of Syk protein-tyrosine kinase to the actin filament network and subsequent association with Fak". European Journal of Biochemistry. 248 (3): 827–33. doi:10.1111/j.1432-1033.1997.00827.x. PMID 9342235.
  32. ^ Dustin LB, Plas DR, Wong J, Hu YT, Soto C, Chan AC, Thomas ML (March 1999). "Expression of dominant-negative src-homology domain 2-containing protein tyrosine phosphatase-1 results in increased Syk tyrosine kinase activity and B cell activation". Journal of Immunology. 162 (5): 2717–24. doi:10.4049/jimmunol.162.5.2717. PMID 10072516.
  33. ^ Deckert M, Tartare-Deckert S, Couture C, Mustelin T, Altman A (December 1996). "Functional and physical interactions of Syk family kinases with the Vav proto-oncogene product". Immunity. 5 (6): 591–604. doi:10.1016/S1074-7613(00)80273-3. PMID 8986718.
  34. ^ Song JS, Gomez J, Stancato LF, Rivera J (October 1996). "Association of a p95 Vav-containing signaling complex with the FcepsilonRI gamma chain in the RBL-2H3 mast cell line. Evidence for a constitutive in vivo association of Vav with Grb2, Raf-1, and ERK2 in an active complex". The Journal of Biological Chemistry. 271 (43): 26962–70. doi:10.1074/jbc.271.43.26962. PMID 8900182.

Further reading

[edit]
[edit]
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Tyrosine-protein_kinase_SYK&oldid=1191707483"